{"id":44977,"date":"2026-09-11T10:24:02","date_gmt":"2026-09-11T08:24:02","guid":{"rendered":"https:\/\/celonpharma.com\/?p=44977"},"modified":"2026-09-11T10:24:04","modified_gmt":"2026-09-11T08:24:04","slug":"current-report-no-17-2026-positive-results-of-the-bioequivalence-study-of-celon-semaglutide-reduzek","status":"publish","type":"post","link":"https:\/\/celonpharma.com\/en\/current-report-no-17-2026-positive-results-of-the-bioequivalence-study-of-celon-semaglutide-reduzek\/","title":{"rendered":"Current Report No. 17\/2026 – Positive Results of the Bioequivalence Study of Celon Semaglutide (Reduzek)"},"content":{"rendered":"\n

Legal basis:<\/strong> Article 17(1) of the Market Abuse Regulation (MAR) \u2013 Inside Information
Date and time:<\/strong> 20 August 2026, 11:33<\/p>\n\n\n\n

The Management Board of Celon Pharma S.A. (the \u201cCompany\u201d) hereby announces that the Company has obtained positive results from a bioequivalence study of its semaglutide-containing medicinal product, Reduzek, currently under development by the Company.<\/p>\n\n\n\n

The objective of the study was to demonstrate the bioequivalence of Celon Semaglutide 0.5 mg (Reduzek) to the reference medicinal products Wegovy\u00ae (semaglutide) 0.5 mg and Ozempic\u00ae (semaglutide) 0.5 mg, administered subcutaneously.<\/p>\n\n\n\n

The study was designed as a randomized, open-label, single-dose, parallel-group bioequivalence study and was conducted under fasting conditions in 91 healthy volunteers in Canada.<\/p>\n\n\n\n

The study demonstrated the bioequivalence of Celon Semaglutide 0.5 mg (Reduzek) to both Wegovy\u00ae and Ozempic\u00ae. For the primary pharmacokinetic parameters, AUC(0\u2013t) and Cmax, the 90% confidence intervals for the ratios of geometric means fell within the predefined bioequivalence acceptance range of 80.00%\u2013125.00%, in accordance with the ICH M13A guideline.<\/p>\n\n\n\n

The results confirm that the rate and extent of absorption of Celon Semaglutide (Reduzek) are comparable to those of the reference medicinal products Wegovy\u00ae and Ozempic\u00ae, thereby confirming that the applicable bioequivalence criteria have been met.<\/p>\n\n\n\n

The positive results of the study enable the bioequivalence findings to be extrapolated to the remaining strengths of the products, in accordance with the applicable bioequivalence guidelines.<\/p>\n\n\n\n

The study represents a significant milestone in the development of Celon Semaglutide (Reduzek) as an equivalent of Novo Nordisk\u2019s Ozempic\u00ae and Wegovy\u00ae medicinal products and constitutes an important element of the Company\u2019s strategy for the future commercialization of the product in global markets.<\/p>\n","protected":false},"excerpt":{"rendered":"

Legal basis: Article 17(1) of the Market Abuse Regulation (MAR) \u2013 Inside InformationDate and time: 20 August 2026, 11:33 The Management Board of Celon Pharma S.A. (the \u201cCompany\u201d) hereby announces that the Company has obtained positive results from a bioequivalence study of its semaglutide-containing medicinal product, Reduzek, currently under development by the Company. The objectiveRead more »<\/a><\/p>\n","protected":false},"author":20,"featured_media":31750,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[46],"tags":[],"class_list":["post-44977","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-current-reports"],"acf":[],"yoast_head":"\nCurrent Report No. 17\/2026 - Positive Results of the Bioequivalence Study of Celon Semaglutide (Reduzek) - Celon Pharma<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/celonpharma.com\/en\/current-report-no-17-2026-positive-results-of-the-bioequivalence-study-of-celon-semaglutide-reduzek\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Current Report No. 17\/2026 - Positive Results of the Bioequivalence Study of Celon Semaglutide (Reduzek) - Celon Pharma\" \/>\n<meta property=\"og:description\" content=\"Legal basis: Article 17(1) of the Market Abuse Regulation (MAR) \u2013 Inside InformationDate and time: 20 August 2026, 11:33 The Management Board of Celon Pharma S.A. (the \u201cCompany\u201d) hereby announces that the Company has obtained positive results from a bioequivalence study of its semaglutide-containing medicinal product, Reduzek, currently under development by the Company. The objectiveRead more »\" \/>\n<meta property=\"og:url\" content=\"https:\/\/celonpharma.com\/en\/current-report-no-17-2026-positive-results-of-the-bioequivalence-study-of-celon-semaglutide-reduzek\/\" \/>\n<meta property=\"og:site_name\" content=\"Celon Pharma\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-11T08:24:02+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-09-11T08:24:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/celonpharma.com\/wp-content\/uploads\/2023\/09\/Projekt-bez-nazwy-2.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1050\" \/>\n\t<meta property=\"og:image:height\" content=\"600\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Ma\u0142gorzata Siewierska\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Ma\u0142gorzata Siewierska\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/current-report-no-17-2026-positive-results-of-the-bioequivalence-study-of-celon-semaglutide-reduzek\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/current-report-no-17-2026-positive-results-of-the-bioequivalence-study-of-celon-semaglutide-reduzek\\\/\"},\"author\":{\"name\":\"Ma\u0142gorzata Siewierska\",\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/#\\\/schema\\\/person\\\/086a66251c93953fa818392fd883740c\"},\"headline\":\"Current Report No. 17\\\/2026 – Positive Results of the Bioequivalence Study of Celon Semaglutide (Reduzek)\",\"datePublished\":\"2026-09-11T08:24:02+00:00\",\"dateModified\":\"2026-09-11T08:24:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/current-report-no-17-2026-positive-results-of-the-bioequivalence-study-of-celon-semaglutide-reduzek\\\/\"},\"wordCount\":273,\"image\":{\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/current-report-no-17-2026-positive-results-of-the-bioequivalence-study-of-celon-semaglutide-reduzek\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/celonpharma.com\\\/wp-content\\\/uploads\\\/2023\\\/09\\\/Projekt-bez-nazwy-2.png\",\"articleSection\":[\"Current reports\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/current-report-no-17-2026-positive-results-of-the-bioequivalence-study-of-celon-semaglutide-reduzek\\\/\",\"url\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/current-report-no-17-2026-positive-results-of-the-bioequivalence-study-of-celon-semaglutide-reduzek\\\/\",\"name\":\"Current Report No. 17\\\/2026 - Positive Results of the Bioequivalence Study of Celon Semaglutide (Reduzek) - Celon Pharma\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/current-report-no-17-2026-positive-results-of-the-bioequivalence-study-of-celon-semaglutide-reduzek\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/current-report-no-17-2026-positive-results-of-the-bioequivalence-study-of-celon-semaglutide-reduzek\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/celonpharma.com\\\/wp-content\\\/uploads\\\/2023\\\/09\\\/Projekt-bez-nazwy-2.png\",\"datePublished\":\"2026-09-11T08:24:02+00:00\",\"dateModified\":\"2026-09-11T08:24:04+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/#\\\/schema\\\/person\\\/086a66251c93953fa818392fd883740c\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/current-report-no-17-2026-positive-results-of-the-bioequivalence-study-of-celon-semaglutide-reduzek\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/celonpharma.com\\\/en\\\/current-report-no-17-2026-positive-results-of-the-bioequivalence-study-of-celon-semaglutide-reduzek\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/current-report-no-17-2026-positive-results-of-the-bioequivalence-study-of-celon-semaglutide-reduzek\\\/#primaryimage\",\"url\":\"https:\\\/\\\/celonpharma.com\\\/wp-content\\\/uploads\\\/2023\\\/09\\\/Projekt-bez-nazwy-2.png\",\"contentUrl\":\"https:\\\/\\\/celonpharma.com\\\/wp-content\\\/uploads\\\/2023\\\/09\\\/Projekt-bez-nazwy-2.png\",\"width\":1050,\"height\":600},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/current-report-no-17-2026-positive-results-of-the-bioequivalence-study-of-celon-semaglutide-reduzek\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Current Report No. 17\\\/2026 – Positive Results of the Bioequivalence Study of Celon Semaglutide (Reduzek)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/\",\"name\":\"Celon Pharma\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/#\\\/schema\\\/person\\\/086a66251c93953fa818392fd883740c\",\"name\":\"Ma\u0142gorzata Siewierska\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Current Report No. 17\/2026 - Positive Results of the Bioequivalence Study of Celon Semaglutide (Reduzek) - Celon Pharma","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/celonpharma.com\/en\/current-report-no-17-2026-positive-results-of-the-bioequivalence-study-of-celon-semaglutide-reduzek\/","og_locale":"en_US","og_type":"article","og_title":"Current Report No. 17\/2026 - Positive Results of the Bioequivalence Study of Celon Semaglutide (Reduzek) - Celon Pharma","og_description":"Legal basis: Article 17(1) of the Market Abuse Regulation (MAR) \u2013 Inside InformationDate and time: 20 August 2026, 11:33 The Management Board of Celon Pharma S.A. (the \u201cCompany\u201d) hereby announces that the Company has obtained positive results from a bioequivalence study of its semaglutide-containing medicinal product, Reduzek, currently under development by the Company. The objectiveRead more »","og_url":"https:\/\/celonpharma.com\/en\/current-report-no-17-2026-positive-results-of-the-bioequivalence-study-of-celon-semaglutide-reduzek\/","og_site_name":"Celon Pharma","article_published_time":"2026-09-11T08:24:02+00:00","article_modified_time":"2026-09-11T08:24:04+00:00","og_image":[{"width":1050,"height":600,"url":"https:\/\/celonpharma.com\/wp-content\/uploads\/2023\/09\/Projekt-bez-nazwy-2.png","type":"image\/png"}],"author":"Ma\u0142gorzata Siewierska","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Ma\u0142gorzata Siewierska","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/celonpharma.com\/en\/current-report-no-17-2026-positive-results-of-the-bioequivalence-study-of-celon-semaglutide-reduzek\/#article","isPartOf":{"@id":"https:\/\/celonpharma.com\/en\/current-report-no-17-2026-positive-results-of-the-bioequivalence-study-of-celon-semaglutide-reduzek\/"},"author":{"name":"Ma\u0142gorzata Siewierska","@id":"https:\/\/celonpharma.com\/en\/#\/schema\/person\/086a66251c93953fa818392fd883740c"},"headline":"Current Report No. 17\/2026 – Positive Results of the Bioequivalence Study of Celon Semaglutide (Reduzek)","datePublished":"2026-09-11T08:24:02+00:00","dateModified":"2026-09-11T08:24:04+00:00","mainEntityOfPage":{"@id":"https:\/\/celonpharma.com\/en\/current-report-no-17-2026-positive-results-of-the-bioequivalence-study-of-celon-semaglutide-reduzek\/"},"wordCount":273,"image":{"@id":"https:\/\/celonpharma.com\/en\/current-report-no-17-2026-positive-results-of-the-bioequivalence-study-of-celon-semaglutide-reduzek\/#primaryimage"},"thumbnailUrl":"https:\/\/celonpharma.com\/wp-content\/uploads\/2023\/09\/Projekt-bez-nazwy-2.png","articleSection":["Current reports"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/celonpharma.com\/en\/current-report-no-17-2026-positive-results-of-the-bioequivalence-study-of-celon-semaglutide-reduzek\/","url":"https:\/\/celonpharma.com\/en\/current-report-no-17-2026-positive-results-of-the-bioequivalence-study-of-celon-semaglutide-reduzek\/","name":"Current Report No. 17\/2026 - Positive Results of the Bioequivalence Study of Celon Semaglutide (Reduzek) - Celon Pharma","isPartOf":{"@id":"https:\/\/celonpharma.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/celonpharma.com\/en\/current-report-no-17-2026-positive-results-of-the-bioequivalence-study-of-celon-semaglutide-reduzek\/#primaryimage"},"image":{"@id":"https:\/\/celonpharma.com\/en\/current-report-no-17-2026-positive-results-of-the-bioequivalence-study-of-celon-semaglutide-reduzek\/#primaryimage"},"thumbnailUrl":"https:\/\/celonpharma.com\/wp-content\/uploads\/2023\/09\/Projekt-bez-nazwy-2.png","datePublished":"2026-09-11T08:24:02+00:00","dateModified":"2026-09-11T08:24:04+00:00","author":{"@id":"https:\/\/celonpharma.com\/en\/#\/schema\/person\/086a66251c93953fa818392fd883740c"},"breadcrumb":{"@id":"https:\/\/celonpharma.com\/en\/current-report-no-17-2026-positive-results-of-the-bioequivalence-study-of-celon-semaglutide-reduzek\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/celonpharma.com\/en\/current-report-no-17-2026-positive-results-of-the-bioequivalence-study-of-celon-semaglutide-reduzek\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/celonpharma.com\/en\/current-report-no-17-2026-positive-results-of-the-bioequivalence-study-of-celon-semaglutide-reduzek\/#primaryimage","url":"https:\/\/celonpharma.com\/wp-content\/uploads\/2023\/09\/Projekt-bez-nazwy-2.png","contentUrl":"https:\/\/celonpharma.com\/wp-content\/uploads\/2023\/09\/Projekt-bez-nazwy-2.png","width":1050,"height":600},{"@type":"BreadcrumbList","@id":"https:\/\/celonpharma.com\/en\/current-report-no-17-2026-positive-results-of-the-bioequivalence-study-of-celon-semaglutide-reduzek\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/celonpharma.com\/en\/"},{"@type":"ListItem","position":2,"name":"Current Report No. 17\/2026 – Positive Results of the Bioequivalence Study of Celon Semaglutide (Reduzek)"}]},{"@type":"WebSite","@id":"https:\/\/celonpharma.com\/en\/#website","url":"https:\/\/celonpharma.com\/en\/","name":"Celon Pharma","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/celonpharma.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/celonpharma.com\/en\/#\/schema\/person\/086a66251c93953fa818392fd883740c","name":"Ma\u0142gorzata Siewierska"}]}},"_links":{"self":[{"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/posts\/44977","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/users\/20"}],"replies":[{"embeddable":true,"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/comments?post=44977"}],"version-history":[{"count":1,"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/posts\/44977\/revisions"}],"predecessor-version":[{"id":44978,"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/posts\/44977\/revisions\/44978"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/media\/31750"}],"wp:attachment":[{"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/media?parent=44977"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/categories?post=44977"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/tags?post=44977"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}